Official Title
Prospective Randomized Open-label Trial of Atorvastatin as Adjunctive Treatment of COVID-19
Brief Summary

Objective: To assess whether adjunctive therapy of COVID-19 infection with atorvastatin reduces the deterioration in hospitalized patients and improves clinical outcome.

Detailed Description

COVID-19 is caused by SARS-CoV-2, a β-coronavirus that binds to the zinc peptidase
angiotensin-converting enzyme 2 (ACE2). No drug is licensed to treat COVID-19, but adjunctive
pharmacologic interventions have been proposed for their immunomodulatory effects, including
statins. About 5% of cases are considered critical, with severe respiratory failure as well
as myocarditis, and thromboses, and are associated with high fatality rate. Statins affect
endothelial dysfunction and have anti-inflammatory and immunomodulatory effects.

This prospective, randomized, open-label trial of atorvastatin as adjunctive treatment of
COVID-19 in hospitalized patients aims to study:

1. Will atorvastatin reduce progression to severe or critical COVID-19 disease and death
compared to standard care?

2. Will atorvastatin lead to improved clinical outcome of COVID-19 disease at 30 days
compared to standard care?

Unknown status
COVID-19

Drug: Atorvastatin

Atorvastatin 40 mg tablet
Other Name: atorvastatin calcium

Eligibility Criteria

Inclusion Criteria:

- Patient aged 18-85 years, admitted with suspected COVID-19 disease based on clinical
criteria (typical upper respiratory symptoms, e.g. runny nose, sore throat, dry cough,
associated with COVID-19 infection).

Exclusion Criteria:

- already on chronic statin therapy, known hypersensitivity or adverse events to
statins, negative nasopharyngeal (NP) swab for SARS-CoV-2, pregnancy and lactation,
need for ICU admission, ALT or AST >2X upper limit of normal; CPK > 5x upper limit of
normal; and creatinine clearance <50%, chronic treatment with colchicine, cyclosporin,
digoxin, fusidic acid, azole antifungals, niacin.

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: 85 Years
Countries
United States
Locations

Mount Auburn Hospital
Cambridge, Massachusetts, United States

Investigator: Lin Chen, MD
Contact: 617-499-5026
lchen@hms.harvard.edu

Contacts

Lin H Chen, MD
617-499-5026
lchen@mah.harvard.edu

Dan Bourque, MD
617-499-5026
dbourque@mah.harvard.edu

Lin H Chen, MD, Principal Investigator
Mount Auburn Hospital

Mount Auburn Hospital
NCT Number
MeSH Terms
COVID-19
Atorvastatin